More than this, we initially identified the possible role of IFI30 in tumor immunotherapy by systematic and large-scale pan-cancer GSEA analysis, and validated this conclusion by multiple immune assessment algorithms and correlation analysis of tumor immune micro environment (TIME) features. Here, IFI30 is linked to neoplasm.